Media coverage about Taro Pharmaceutical Industries (NYSE:TARO) has been trending positive on Saturday, Accern reports. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Taro Pharmaceutical Industries earned a news impact score of 0.31 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.8084482687588 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Separately, BidaskClub lowered shares of Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday, October 12th.
Taro Pharmaceutical Industries (TARO) traded down $2.19 during trading on Friday, reaching $105.07. 223,888 shares of the company’s stock were exchanged, compared to its average volume of 85,634. Taro Pharmaceutical Industries has a 12 month low of $94.00 and a 12 month high of $128.46. The firm has a market cap of $4,210.00, a price-to-earnings ratio of 12.96 and a beta of 0.62.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.